Clinical trial · Interventional
Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma
COMPARE: Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Patients With Multiple Myeloma
NCT02739594CI-TRIAL-00023210COMPAREterminatedPhase 3Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Slow recruitment
Summary
Brief summary (as posted)
This multicenter, open-label trial will randomize participants with multiple myeloma to a regimen of ibandronate or zoledronate in order to compare the incidence of nephrotoxicity, measured as creatinine clearance (CrCl) reduction greater than (\>) 30 percent (%) or an absolute value of 30 milliliters per minute (mL/min) or lower.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ibandronate | Drug | Ibandronic Acid | ALIAS |
| Zoledronate | Drug | Zoledronic Acid | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Ibandronate
- description
- Participants with multiple myeloma will be randomized to receive ibandronate every 4 weeks for a planned duration of 92 weeks.
- interventionNames
- Drug: Ibandronate
- type
- ACTIVE_COMPARATOR
- label
- Zoledronate
- description
- Participants with multiple myeloma will be randomized to receive zoledronate every 4 weeks for a planned duration of 92 weeks.
- interventionNames
- Drug: Zoledronate
Primary outcomes (2)
- measure
- Percentage of Participants With Deterioration in Renal Function According to Reduction in Creatinine Clearance (CrCl) From Baseline to Week 44
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Confirmed multiple myeloma, Stage II-III as per Salmon and Durie (1975) * Indication for biphosphonate therapy Exclusion Criteria: * Previous therapy with ibandronate or zoledronate within the past 12 months * Renal insufficiency with serum creatinine \>3.0 mg/dL or \>265 micromoles per liter (µmol/L) or CrCl \<30 mL/min * Hypersensitivity to ibandronate, zoledronate, or other biphosphonates * Presence of secondary malignomas, apart from basaliomas and cervical carcinoma in situ * Severe accompanying illness with organ impairment * Osteonecrosis of the jaw at the start of the study * Life expectancy ≤12 months
References
Publications (0)
Data not yet available
No reference posted for this study.